Navigation Links
Specialty Pharmaceutical Industry - 2011 Yearbook
Date:8/30/2011

NEW YORK, Aug. 30, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Specialty Pharmaceutical Industry - 2011 Yearbook

http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Summary

GBI Research's "Specialty Pharmaceutical Industry - 2011 Yearbook" essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

Scope

The report covers -

- Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.

- Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.

- Data and analysis on the specialty pharmaceutical market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 9

2 Specialty Pharmaceutical Market- 2011 Yearbook: Introduction 12

2.1 Scope 12

2.2 GBI Research Report Guidance 12

3 Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market 13

3.1 Disease Overview 13

3.2 Market Overview 14

3.3 Global HIV Therapeutics Market: Market Characterization 14

3.3.1 Market Forecasts 14

3.3.2 Annual Cost of Therapy 16

3.3.3 Usage Patterns 18

3.3.4 Geographical Distribution 24

3.4 HIV Therapeutics Market: Drivers and Restraints 26

3.4.1 Market Drivers 26

3.4.2 Market Restraints 29

4 Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder 31

4.1 Disease Overview 31

4.2 Market Overview 31

4.3 Age Related Macular Degenerative Disorder: Market Characterization 32

4.3.1 Market Forecasts 32

4.3.2 Geographical Distribution 33

4.3.3 Annual Cost of Therapy 34

4.3.4 Usage Patterns 35

4.4 Age Related Macular Degenerative Disorder: Drivers and Restraints 39

4.4.1 Market Drivers 39

4.4.2 Market Restraints 40

5 Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD) 41

5.1 Introduction 41

5.2 Attention Deficit Hyperactive Disorder: Market Characterization 41

5.2.1 Market Forecasts 41

5.2.2 Geographical Distribution 43

5.2.3 Annual Cost of Therapy 44

5.2.4 Usage Patterns 45

5.3 Attention Deficit Hyperactive Disorder Market: Drivers and Restraints 50

5.3.1 Market Drivers 50

5.3.2 Market Restraints 50

6 Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimer's Disease 51

6.1 Introduction 51

6.2 Alzheimer's disease: Market Characterization 51

6.2.1 Market Forecasts 51

6.2.2 Geographical Distribution 53

6.2.3 Annual Cost of Therapy 54

6.2.4 Usage Patterns 55

6.3 Alzheimer's Disease Market: Drivers and Restraints 60

6.4 Market Drivers 60

6.5 Market Restraints 60

7 Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer 61

7.1 Introduction 61

7.2 Colorectal Cancer: Market Characterization 61

7.2.1 Market Forecasts 61

7.2.2 Geographical Distribution 63

7.2.3 Annual Cost of Therapy 64

7.2.4 Usage Patterns 65

7.3 Colorectal Cancer Market: Drivers and Restraints 70

7.3.1 Market Drivers 70

7.3.2 Market Restraints 70

8 Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis 71

8.1 Introduction 71

8.2 Rheumatoid Arthritis: Market Characterization 71

8.2.1 Market Forecasts 71

8.2.2 Annual Cost of Therapy 73

8.2.3 Treatment Usage Patterns 74

8.2.4 Geographical Distribution 79

8.3 Rheumatoid Arthritis Market: Drivers and Restraints 80

8.3.1 Market Drivers 80

8.3.2 Market Restraints 80

9 Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy 81

9.1 Introduction 81

9.2 Epilepsy: Market Characterization 81

9.2.1 Market Forecasts 81

9.2.2 Geographical Distribution 83

9.2.3 Annual Cost of Therapy 84

9.2.4 Usage Patterns 85

9.3 Epilepsy Market: Drivers and Restraints 90

9.3.1 Market Drivers 90

9.3.2 Market Restraints 90

10 Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma 91

10.1 Introduction 91

10.2 Glaucoma: Market Characterization 91

10.2.1 Market Forecasts 91

10.2.2 Geographical Distribution 93

10.2.3 Annual Cost of Therapy 94

10.2.4 Usage Patterns 95

10.3 Glaucoma Market: Drivers and Restraints 100

10.3.1 Drivers of the Glaucoma Market 100

10.3.2 Barriers for the Glaucoma Market 100

11 Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis 102

11.1 Specialty Pharmaceutical Pipeline: HIV market 105

11.2 Molecule Profile for Promising Drugs under Clinical Development: HIV 106

11.2.1 Rilpivirine hydrochloride (TMC278) 106

11.2.2 Elvitegravir 107

11.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 108

11.2.4 Racivir 109

11.2.5 Apricitabine (ATC) 110

11.2.6 Tesamorelin 111

11.3 Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration 112

11.4 Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration 113

11.4.1 VEGF Trap-Eye 113

11.5 Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder 114

11.6 Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder 115

11.6.1 ABT-894 (Sofinicline) 115

11.6.2 Eltoprazine 115

11.6.3 AZD3480 (TC-1734) (Isopronicline) 116

11.7 Specialty Pharmaceutical Pipeline: Alzheimer's Disease 117

11.8 Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer's Disease 118

11.8.1 Bapineuzumab 118

11.8.2 Gammagard 119

11.8.3 Dimebon 120

11.8.4 Rember (Trx0014) (methylthionium chloride) 120

11.9 Specialty Pharmaceutical Pipeline: Colorectal Cancer 122

11.10 Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer 123

11.10.1 Aflibercept 123

11.10.2 Brivanib 124

11.10.3 OncoVAX 125

11.10.4 TroVax 127

11.10.5 KRX-0401 (Perifosine) 128

11.11 Specialty Pharmaceutical Pipeline: Rheumatoid Arthritis 129

11.12 Profiles for Promising Drugs under Clinical Development: Rheumatoid Arthritis 130

11.12.1 T-614 (iguratimod) 130

11.12.2 CP-690550 130

11.12.3 Arzerra (HuMax-CD20 /Ofatumumab) 131

11.12.4 VX-509 132

11.13 Specialty Pharmaceutical Pipeline: Epilepsy 133

11.14 Molecule Profile for Promising Drugs under Clinical Development: Epilepsy 134

11.14.1 Stedesa (Eslicarbazepine Acetate) 134

11.14.2 Comfyde (Carisbamate) 135

11.14.3 Retigabine 136

11.14.4 Brivaracetam 137

11.14.5 Ganaxolone 137

11.14.6 E2007 (Perampanel) 138

11.15 Specialty Pharmaceutical Pipeline: Glaucoma 139

11.16 Molecule Profile for Promising Drugs under Clinical Development: Glaucoma 140

11.16.1 Tafluprost (Saflutan) 140

11.16.2 NCX-116 (Formerly PF-03187207) 141

12 Specialty Pharmaceutical Market- 2011 Yearbook: Strategic Consolidations 142

12.1 Mergers and Acquisitions 142

12.1.1 Pfizer 144

12.1.2 F. Hoffmann-La Roche 146

12.1.3 GlaxoSmithKline 146

12.2 Licensing Deals 148

12.2.1 Pfizer 149

12.2.2 F. Hoffmann-La Roche 151

12.2.3 GlaxoSmithKline 153

12.3 Co-Development Deals 155

12.3.1 Pfizer 156

12.3.2 F. Hoffmann-La Roche 158

12.3.3 GlaxoSmithKline 160

13 Specialty Pharmaceutical Market- 2011 Yearbook: Appendix 162

13.1 Market Definitions 162

13.2 Abbreviations 162

13.3 Research Methodology 163

13.3.1 Coverage 163

13.3.2 Secondary Research 164

13.3.3 Primary Research 164

13.3.4 Forecasts 164

13.3.5 Expert Panel Validation 167

13.4 Contact Us 167

13.5 Disclaimer 167

13.6 Sources 167

List of Tables

1.1 List of Tables

Table 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 2001–2009 15

Table 2: Specialty Pharmaceutical Market, HIV Market, Global, Revenue ($m), 2009–2017 15

Table 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 16

Table 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2017 17

Table 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2001–2009 19

Table 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2001–2009 19

Table 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2001-2009 24

Table 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2009-2017 24

Table 9: HIV Therapeutics Market, Global, Key Drugs Going Off Patent, 2008–2016 29

Table 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2001-2009 32

Table 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2009-2017 32

Table 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues , 2001–2009 33

Table 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues, 2010–2017 33

Table 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2009 34

Table 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2009-2017 34

Table 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2001–2009 35

Table 17: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2009–2017 35

Table 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2001-2009 42

Table 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2009-2017 42

Table 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 2001–2009 43

Table 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 2009–2017 43

Table 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2009 44

Table 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2009-2017 44

Table 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2001–2009 45

Table 25: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2009–2017 45

Table 26: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Revenue ($m), 2001-2009 51

Table 27: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Revenue ($m), 2009-2017 52

Table 28: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Geographical Distribution of Revenues ($m), 2001–2009 53

Table 29: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Geographical Distribution of Revenues ($m), 2009–2017 53

Table 30: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Annual Cost of Therapy ($), 2001-2009 54

Table 31: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Annual Cost of Therapy ($), 2009-2017 54

Table 32: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Usage Patterns, 2001–2009 55

Table 33: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Usage Patterns, 2009–2017 55

Table 34: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2001-2009 62

Table 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2009-2017 62

Table 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 2001–2009 63

Table 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 2009–2017 63

Table 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2009 64

Table 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2009-2017 64

Table 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2001–2009 65

Table 41: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2009–2017 66

Table 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2001-2009 72

Table 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2009-2017 72

Table 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2009 73

Table 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2009-2017 73

Table 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2001–2009 74

Table 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2009–2017 74

Table 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 2001–2009 79

Table 49: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 2009–2017 79

Table 50: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2001-2009 82

Table 51: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2009-2017 82

Table 52: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2001–2009 83

Table 53: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2009–2017 83

Table 54: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2009 84

Table 55: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017 84

Table 56: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2001–2009 85

Table 57: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2009–2017 85

Table 58: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2001-2009 92

Table 59: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2009-2017 92

Table 60: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2001–2009 93

Table 61: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2009–2017 93

Table 62: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2009 94

Table 63: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017 94

Table 64: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2001–2009 95

Table 65: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2009–2017 96

Table 66: Specialty Pharmaceutical Market, M&A, Pfizer, 2004 to 2010 144

Table 67: Specialty Pharmaceutical Market, M&A, F. Hoffmann-La Roche, 2004 to 2010 146

Table 68: Specialty Pharmaceutical Market, M&A, GlaxoSmithKline, 2004 to 2010 146

Table 69: Specialty Pharmaceutical Market, Licensing Deals, Pfizer, 2004 to 2010 149

Table 70: Specialty Pharmaceutical Market, Licensing Deals , F. Hoffmann-La Roche, 2004 to 2010 151

Table 71: Specialty Pharmaceutical Market, Licensing Deals, GlaxoSmithKline, 2004 to 2010 153

Table 72: Specialty Pharmaceutical Market, Co-development Deals, Pfizer, 2004-2010 156

Table 73: Specialty Pharmaceutical Market, Co-development Deals, F. Hoffmann-La Roche, 2004-2010 158

Table 74: Specialty Pharmaceutical Market, Co-development Deals, GlaxoSmithKline, 2004-2010 160

List of Figures

1.2 List of Figures

Figure 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), 2001-2017 14

Figure 2: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2017 16

Figure 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2000–2016 18

Figure 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diseased Population, 2001–2017 20

Figure 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Treatment Seeking Population, 2001–2017 21

Figure 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diagnosis Population, 2000–2016 22

Figure 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Prescription Population, 2000–2016 23

Figure 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 2001–2017 24

Figure 9: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($bn), 2001-2017 32

Figure 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues ($bn), 2001–2017 33

Figure 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2017 34

Figure 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2000–2017 35

Figure 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diseased Population, 2001–2017 36

Figure 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Treatment Seeking Population, 2001–2017 37

Figure 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diagnosis Population, 2001–2017 38

Figure 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Prescription Population, 2001–2017 39

Figure 17: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($bn), 2001-2017 41

Figure 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($bn), 2001–2017 43

Figure 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2017 44

Figure 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2001–2017 45

Figure 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diseased Population, 2001–2017 46

Figure 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Treatment Seeking Population, 2001–2017 47

Figure 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diagnosis Population, 2001–2017 48

Figure 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Prescription Population, 2001–2017 49

Figure 25: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Revenue ($bn), 2001-2017 51

Figure 26: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Geographical Distribution of Revenues ($bn), 2001–2017 53

Figure 27: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Annual Cost of Therapy ($), 2001-2017 54

Figure 28: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Usage Patterns, 2001–2017 55

Figure 29: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Diseased Population, 2001–2017 56

Figure 30: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Treatment Seeking Population, 2001–2017 57

Figure 31: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Diagnosis Population, 2001–2017 58

Figure 32: Specialty Pharmaceutical Market, Alzheimer's Disease, Global, Prescription Population, 2001–2017 59

Figure 33: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($bn), 2001-2017 61

Figure 34: Specialty Pharmaceutical Market Colorectal Cancer, Global, Geographical Distribution of Revenues ($bn), 2001–2017 63

Figure 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2017 64

Figure 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2001–2017 65

Figure 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diseased Population, 2001–2017 66

Figure 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Treatment Seeking Population, 2001–2017 67

Figure 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diagnosis Population, 2001–2017 68

Figure 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Prescription Population, 2001–2017 69

Figure 41: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($bn), 2001-2017 71

Figure 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2017 73

Figure 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2001–2017 74

Figure 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diseased Population, 2001–2017 75

Figure 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Treatment Seeking Population, 2001–2017 76

Figure 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diagnosis Population, 2001–2017 77

Figure 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Prescription Population, 2001–2017 78

Figure 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($bn), 2001–2017 79

Figure 49: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($bn), 2001-2017 81

Figure 50: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($bn), 2001–2017 83

Figure 51: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2017 84

Figure 52: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2001–2017 85

Figure 53: Specialty Pharmaceutical Market, Epilepsy, Global, Diseased Population, 2001–2017 86

Figure 54: Specialty Pharmaceutical Market, Epilepsy, Global, Treatment Seeking Population, 2001–2017 87

Figure 55: Specialty Pharmaceutical Market, , Epilepsy, Global, Diagnosis Population, 2001–2017 88

Figure 56: Specialty Pharmaceutical Market, Epilepsy, Global, Prescription Population, 2001–2017 89

Figure 57: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($bn), 2001-2017 91

Figure 58: Specialty Pharmaceutical Market, Glaucoma, Global, Geographical Distribution of Revenues ($bn), 2001–2017 93

Figure 59: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2017 94

Figure 60: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2001–2017 95

Figure 61: Specialty Pharmaceutical Market, Glaucoma, Global, Diseased Population, 2001–2017 96

Figure 62: Specialty Pharmaceutical Market, Glaucoma, Global, Treatment Seeking Population, 2001–2017 97

Figure 63: Specialty Pharmaceutical Market, Glaucoma, Global, Diagnosis Population, 2001–2017 98

Figure 64: Specialty Pharmaceutical Market, Glaucoma, Global, Prescription Population, 2001–2017 99

Figure 65: Specialty Pharmaceutical Market, Pipeline, Indication, 2010 102

Figure 66: Specialty Pharmaceutical Market, Pipeline, Phase Analysis, 2010 103

Figure 67: Specialty Pharmaceutical Market, Pipeline, By Indication, 2010 104

Figure 68: Specialty Pharmaceutical Market, Pipeline, HIV, 2010 105

Figure 69: Specialty Pharmaceutical Market, Pipeline, Age Related Macular Degeneration, 2010 112

Figure 70: Specialty Pharmaceutical Market, Pipeline Attention Deficit Hyperactive Disorder, 2010 114

Figure 71: Specialty Pharmaceutical Market, Pipeline, Alzheimer's Disease, 2010 117

Figure 72: Specialty Pharmaceutical Market, Pipeline, Colorectal Cancer, 2010 122

Figure 73: Specialty Pharmaceutical Market, Pipeline, Rheumatoid Arthritis, 2010 129

Figure 74: Specialty Pharmaceutical Market, Pipeline, Epilepsy, 2010 133

Figure 75: Specialty Pharmaceutical Market, Pipeline, Glaucoma, 2010 139

Figure 76: Specialty Pharmaceutical Market, M&A, Year on Year, 2004 to 2010 142

Figure 77: Specialty Pharmaceutical Market, M&A, By Indication, 2004 to 2010 143

Figure 78: Specialty Pharmaceutical Market, M&A, Deal Type, 2004 to 2010 144

Figure 79: Specialty Pharmaceutical Market, Licensing Deals, Year on Year, 2004 to 2010 148

Figure 80: Specialty Pharmaceutical Market, Licensing Deals, By Indication, 2004 to 2010 148

Figure 81: Specialty Pharmaceutical Market, Co-development Deals, Year on Year, 2004 to 2010 155

Figure 82: Specialty Pharmaceutical Market, Co-development Deals, By Indication, 2004 to 2010 155

Figure 83: GBI Research Market Forecasting Model 166

To order this report:

Pathology Industry: Specialty Pharmaceutical Industry - 2011 Yearbook

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. U.S. Preventive Medicine Acquires Specialty Disease Management
3. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
4. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
5. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
6. Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
7. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
8. Sarnova Acquires Metropolitan Medical to Expand Portfolio of Specialty Health Care Products
9. Statement of Americas Specialty Medicines Companies On House Health Care Bill (H.R. 3962)
10. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
11. Sarnova Announces Acquisition of CVC, Inc. to Expand Portfolio of Specialty Medical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016 Global Pulmonary ... drugs studies the current as well as future ... this report include companies and intermediaries engaged in ... and/or drug-device combinations as well as new entrants ... an elaborate executive summary along with a market ...
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty ... IV Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites. ... diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the work we have ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... When it came time to blow out ... Just 40 minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s ... the Weston teen the hospital’s 30th heart transplant recipient. , “He was playing at ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
Breaking Medicine News(10 mins):